JP2022501334A5 - - Google Patents

Info

Publication number
JP2022501334A5
JP2022501334A5 JP2021513960A JP2021513960A JP2022501334A5 JP 2022501334 A5 JP2022501334 A5 JP 2022501334A5 JP 2021513960 A JP2021513960 A JP 2021513960A JP 2021513960 A JP2021513960 A JP 2021513960A JP 2022501334 A5 JP2022501334 A5 JP 2022501334A5
Authority
JP
Japan
Prior art keywords
alkyl
salt
alkoxy
cycloalkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513960A
Other languages
English (en)
Japanese (ja)
Other versions
JP7434294B2 (ja
JP2022501334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050721 external-priority patent/WO2020056074A1/en
Publication of JP2022501334A publication Critical patent/JP2022501334A/ja
Publication of JP2022501334A5 publication Critical patent/JP2022501334A5/ja
Application granted granted Critical
Publication of JP7434294B2 publication Critical patent/JP7434294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513960A 2018-09-13 2019-09-12 キナーゼ阻害剤としてのインダゾールカルボキサミド Active JP7434294B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730611P 2018-09-13 2018-09-13
US62/730,611 2018-09-13
PCT/US2019/050721 WO2020056074A1 (en) 2018-09-13 2019-09-12 Indazole carboxamides as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2022501334A JP2022501334A (ja) 2022-01-06
JP2022501334A5 true JP2022501334A5 (cg-RX-API-DMAC7.html) 2022-09-05
JP7434294B2 JP7434294B2 (ja) 2024-02-20

Family

ID=68073172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513960A Active JP7434294B2 (ja) 2018-09-13 2019-09-12 キナーゼ阻害剤としてのインダゾールカルボキサミド

Country Status (14)

Country Link
US (1) US12084426B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849969B1 (cg-RX-API-DMAC7.html)
JP (1) JP7434294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102793119B1 (cg-RX-API-DMAC7.html)
CN (1) CN112673001B (cg-RX-API-DMAC7.html)
AU (1) AU2019339355A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004310A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112519A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190759A1 (cg-RX-API-DMAC7.html)
ES (1) ES2945220T3 (cg-RX-API-DMAC7.html)
IL (1) IL281371A (cg-RX-API-DMAC7.html)
MX (1) MX2021002617A (cg-RX-API-DMAC7.html)
SG (1) SG11202102406XA (cg-RX-API-DMAC7.html)
WO (1) WO2020056074A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111566103B (zh) 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
KR102793119B1 (ko) 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
KR20230100646A (ko) 2021-12-24 2023-07-05 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2008525464A (ja) 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−7ニコチン性受容体リガンド並びにその製造及び使用
NZ573735A (en) 2006-05-19 2011-10-28 Abbott Lab Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
KR20130077390A (ko) 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
EA024939B1 (ru) 2012-02-21 2016-11-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
WO2013124169A1 (en) 2012-02-21 2013-08-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
US10933068B2 (en) 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
US10836770B2 (en) * 2016-10-07 2020-11-17 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
LT3580220T (lt) 2017-02-13 2021-12-27 Bristol-Myers Squibb Company Aminotriazolopiridinai, kaip kinazės inhibitoriai
CN111566103B (zh) 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
KR102793119B1 (ko) 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2022512156A5 (cg-RX-API-DMAC7.html)
JP2016513661A5 (cg-RX-API-DMAC7.html)
JP2007519694A5 (cg-RX-API-DMAC7.html)
JP2020527173A5 (cg-RX-API-DMAC7.html)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2017537948A5 (cg-RX-API-DMAC7.html)
RU2009119181A (ru) Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3
JP2016507502A5 (cg-RX-API-DMAC7.html)
JP2021502387A5 (cg-RX-API-DMAC7.html)
RU2007119562A (ru) Тетрациклические производные индолов в качестве противовирусных агентов
JP2012508252A5 (cg-RX-API-DMAC7.html)
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
RU2012156940A (ru) Лекарственные средства, индуцирующие апоптоз, для лечения рака и иммунных и аутоиммунных заболеваний
IL175609A (en) N-acylsulfonamide apoptosis promoters for use in treating diseases during which anti-apoptotic protein family members are expressed
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
JP2022553077A5 (cg-RX-API-DMAC7.html)
JP2020520957A5 (cg-RX-API-DMAC7.html)
RU2010145463A (ru) Производные замещенного 2-фенилпиридина
BR112020001695A2 (pt) compostos macrocíclicos e usos dos mesmos
JP2010527985A5 (cg-RX-API-DMAC7.html)
JP2022542140A5 (cg-RX-API-DMAC7.html)
JP2022500418A5 (cg-RX-API-DMAC7.html)
JP2022533939A5 (cg-RX-API-DMAC7.html)
WO2007132228A1 (en) Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder
JP2018507257A5 (cg-RX-API-DMAC7.html)